Day: September 13, 2022

LA JOLLA, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034. The allowed claims cover the use of MN-001 or MN-002 for reducing a triglyceride blood level, for reducing a total cholesterol blood level, and for reducing a low density lipoprotein (LDL) blood level....

NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRES TORONTO, ON, Sept. 13, 2022 (GLOBE NEWSWIRE) — Pinehurst Capital II Inc. (TSXV: PINH.P) (the “Company”), a Capital Pool Company, as defined in the policies of the TSX Venture Exchange (the “TSXV”), is pleased to announce that, in connection with its previously announced “Qualifying Transaction” (the “Transaction”) pursuant to TSXV Policy 2.4 – Capital Pool Companies (the “CPC Policy”) with Halcones Precious Metals Inc. (“Halcones”), the Company today filed a filing statement in connection with the Transaction (the “Filing Statement”) on the Company’s profile on SEDAR at www.sedar.com. Following the completion of the Transaction, the Company (the “Resulting Issuer”) will carry on the business of Halcones and intends to change its name to “Halcones Precious Metals...

Toronto, Ontario, Sept. 13, 2022 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp (TSXV: MNLX) announced today that its core shareholders representing approximately 75% of the issued and outstanding shares of the Company have recommitted to a voluntary lock-up agreement for the next twelve months. Executive Chairman Anthony Tjan commented, “Core shareholders are committed to the long-term growth and value creation in MiniLuxe as it moves towards a vision of being the leading lifestyle brand and talent empowerment platform for the nail and waxing industry. The lock-up is reflective of shareholders who are aligned with our mission and excited by the company’s intrinsic value and growth trajectory.” About MiniLuxe MiniLuxe, a Delaware corporation based in Boston, Massachusetts is a digital-first, socially-responsible lifestyle brand and talent...

ALBANY, NY, Sept. 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Soluna Holdings, Inc. (“SHI” or the “Company”), (NASDAQ: SLNH), the parent company of Soluna Computing, Inc. (“SCI”), a developer of green data centers for cryptocurrency mining and other intensive computing, today announced that it has entered into a further amendment to its convertible notes (the “Notes”) which were issued on October 25, 2021.  The Company has agreed with the noteholders to amend the terms of the Notes and to extend the Notes’ maturity date until April 25, 2023. The amendment also allows for the Company to have released to it the $1,000,000 currently on deposit, though by October 17, 2022, the Company is required to re-escrow this amount. The Company will also not be required to make the next $950,000 escrow deposit that would have been due on September...

WESTLAKE, Texas, Sept. 13, 2022 (GLOBE NEWSWIRE) — Goosehead Insurance, Inc. (“Goosehead” or the “Company”) (NASDAQ: GSHD), a rapidly growing independent personal lines insurance agency, announced today that the company reiterates its full year 2022 outlook. The Company’s outlook for full year 2022 is as follows:Total written premiums placed for 2022 are expected to be between $2.152 billion and $2.215 billion, representing organic growth of 38% on the low end of the range to 42% on the high end of the range. Total revenues for 2022 are expected to be between $194 million and $205 million, representing organic growth of 28% on the low end of the range to 35% on the high end of the range, driven by high levels of Core Revenue growth partly offset by lower than historical average contingent commissions of $8-10 million for the...

NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer NGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 + gemcitabine + Nab-paclitaxel) with no dose-limiting toxicities As of the March 15, 2022 abstract data cut-off date, among the six evaluable patients in the Phase 1b combination cohort, a disease control rate of 100% was observed, median progression-free survival had not been reached and the 12-month survival rate was 83.3% Three of the six evaluable patients experienced partial responses (PR) extending more than 32 weeks as of the abstract cut-off date, including one patient with a PR that was ongoing at 90 weeks as of August 15, 2022SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals,...

Stellantis and General Motors to Execute a Share Repurchase Transaction AMSTERDAM, Sept. 13, 2022 – Stellantis N.V. and General Motors Holdings LLC, a subsidiary of General Motors Company (“GM”) have executed a share repurchase agreement (“SRA”) related to the 69.1 million common shares in Stellantis, representing approximately 2.2% of Stellantis’ share capital (on a diluted basis), that GM is entitled to receive upon the exercise of equity warrants (the “Warrants”) originally issued by Peugeot S.A. (“PSA”) to GM in 2017. The Warrants were issued to GM as part of the purchase by PSA of the Opel Vauxhall automotive business. Upon exercise of the Warrants, Stellantis will also deliver to GM approximately 1.2 million common shares of Faurecia and an aggregate cash amount of approximately EUR130 million for rights to dividends paid by PSA...